Zymeworks Inc
ZYME16.490USD
+0.620+3.91%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
1.16BMarket Cap
LossP/E TTM
More Details of Zymeworks Inc Company
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.
Company Info
Ticker SymbolZYME
Company nameZymeworks Inc
IPO dateJun 24, 2019
CEOMr. Kenneth H. (Ken) Galbraith
Number of employees280
Security typeOrdinary Share
Fiscal year-endJun 24
Address108 Patriot Drive, Suite A
CityMIDDLETOWN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code19709
Phone13022748744
Websitehttps://www.zymeworks.com/
Ticker SymbolZYME
IPO dateJun 24, 2019
CEOMr. Kenneth H. (Ken) Galbraith
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
Dr. Sabeen Mekan, M.D.
Dr. Sabeen Mekan, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Neil Gallagher, M.D., Ph.D.
Dr. Neil Gallagher, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
Dr. Sabeen Mekan, M.D.
Dr. Sabeen Mekan, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EcoR1 Capital, LLC
30.56%
Rubric Capital Management LP
6.27%
BVF Partners L.P.
5.73%
Redmile Group, LLC
5.52%
Morgan Stanley & Co. LLC
4.82%
Other
47.10%
Shareholders
Shareholders
Proportion
EcoR1 Capital, LLC
30.56%
Rubric Capital Management LP
6.27%
BVF Partners L.P.
5.73%
Redmile Group, LLC
5.52%
Morgan Stanley & Co. LLC
4.82%
Other
47.10%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
50.52%
Investment Advisor
23.12%
Hedge Fund
18.92%
Research Firm
5.96%
Private Equity
1.70%
Individual Investor
0.81%
Venture Capital
0.45%
Pension Fund
0.30%
Sovereign Wealth Fund
0.27%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
383
76.90M
102.73%
+2.83M
2025Q1
400
71.70M
97.61%
-1.37M
2024Q4
389
68.69M
99.73%
-8.79M
2024Q3
388
74.13M
105.03%
-25.13M
2024Q2
387
74.77M
106.29%
-27.88M
2024Q1
389
74.54M
106.20%
-28.73M
2023Q4
388
72.09M
103.65%
-29.69M
2023Q3
376
69.54M
103.06%
-33.91M
2023Q2
364
70.30M
109.70%
-27.74M
2023Q1
340
64.28M
100.47%
-34.07M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
EcoR1 Capital, LLC
22.97M
30.69%
+5.09M
+28.44%
Jun 26, 2025
Rubric Capital Management LP
4.34M
5.8%
+421.11K
+10.75%
Mar 31, 2025
BVF Partners L.P.
4.31M
5.76%
--
--
Mar 31, 2025
Redmile Group, LLC
4.79M
6.4%
-51.52K
-1.06%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.30M
4.42%
-169.56K
-4.88%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.40M
4.54%
-93.86K
-2.69%
Mar 31, 2025
The Vanguard Group, Inc.
1.76M
2.35%
-718.49K
-28.98%
Mar 31, 2025
BNP Paribas Asset Management USA, Inc.
2.20M
2.94%
+222.17K
+11.25%
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
1.38M
1.85%
+812.87K
+142.68%
Mar 31, 2025
UBS Asset Management (Americas) LLC
1.60M
2.14%
+1.60M
--
Mar 31, 2025
View more
Related ETFs
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.13%
Tema Oncology ETF
1.13%
iShares Micro-Cap ETF
0.14%
Federated Hermes MDT Small Cap Core ETF
0.13%
WisdomTree US SmallCap Quality Growth Fund
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
iShares Biotechnology ETF
0.09%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.09%
SPDR S&P International Small Cap ETF
0.06%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.13%
Tema Oncology ETF
Proportion1.13%
iShares Micro-Cap ETF
Proportion0.14%
Federated Hermes MDT Small Cap Core ETF
Proportion0.13%
WisdomTree US SmallCap Quality Growth Fund
Proportion0.1%
ProShares Ultra Nasdaq Biotechnology
Proportion0.1%
iShares Biotechnology ETF
Proportion0.09%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proportion0.09%
Invesco Nasdaq Biotechnology ETF
Proportion0.09%
SPDR S&P International Small Cap ETF
Proportion0.06%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
